Table 2.
Puberty onset characteristics in SRS and SGA groups.
| p-values | ||||||||
|---|---|---|---|---|---|---|---|---|
| SRS | 11p15LOM | UPD7 | SGA | SRS vs SGA | 11p15 vs UPD7 | 11p15 vs SGA | UPD7 vs SGA | |
| Clinical puberty onset (y) | 10.02 ± 1.80 (13 pt) [7.0-13.0] |
11.75 ± 1.14 (5 pt) [10.0-13.0] |
8.94 ± 1.15 (8 pt) [7.0-10.0] |
11.38 ± 1.15 (18 pt) [8.0-13.5] |
0.03 | 0.003 | 0.53 | 0.0001 |
| Clinical puberty onset (y) in males | 11.46 ± 1.25 (6 pt) [8.0-13.0] |
12.13 (4 pt) [11.5-13.0] |
10.0 (2 pt) [10.0] |
11.79 ± 1.48 (12 pt) [8.0-13.5] |
0.61 | - | – | - |
| Clinical puberty onset (y) in females | 8.79 ± 1.15 (7 pt) [7.0-10.0] |
10.0 (1 pt) |
9.0 (6 pt) [7.0-10.0] |
10.57 ± 0.96 (6 pt) [9.25-12.0] |
0.02 | - | – | - |
| Pubarche age (y) | 9.92 ± 1.38 (14 pt) [7.5-11.5] |
10.34 ± 1.66 (7 pt) [7.5-11.5] |
9.49 ± 0.97 (7 pt) [8.0-10.5] |
11.90 ± 1.70 (18 pt) [8.0-14.5] |
0.001 | 0.16 | 0.04 | 0.002 |
| Pubarche age (y) in males | 10.33 ± 1.49 (8 pt) [7.5-11.5] |
11.5 (5 pt) [7.5-11.5] |
10.0 (3 pt) [8.8-10.4] |
12.37 ± 1.80 (12 pt) [8.0-14.5] |
0.01 | – | - | - |
| Pubarche age (y) in females | 9.37 ± 1.10 (6 pt) [8.0-10.5] |
9.50 (2 pt) [8.5-10.5] |
9.38 (4 pt) [8.0-10.5] |
10.97 ± 1.06 (6 pt) [9.8-12.5] |
0.09 | – | - | - |
| Measurable sexual hormones*, age (y) | 9.47 ± 1.44 (12 pt) [7.0-12.3] |
10.12 ± 1.61 (5 pt) [8.0-12.3] |
9.01 ± 1.22 (7 pt) [7.0-10.8] |
11.86 ± 1.28 (19 pt) [9.8-14.7] |
0.0001 | 0.27 | 0.02 | 0.0001 |
| Measurable sexual hormones*, age (y) in males | 9.92 ± 1.36 (8 pt) [8.0-12.3] |
9.82 (5 pt) [8.0-12.3] |
9.19 (3 pt) [8.8-10.8] |
12.09 ± 1.39 (13 pt) [9.9-14.7] |
0.01 | – | - | - |
| Measurable sexual hormones*, age (y) in females | 8.58 ± 1.30 (4 pt) [7.0-10.1] |
0 pt | 8.59 (4 pt) [7.0-10.1] |
11.38 ± 0.95 (6 pt) [9.8-12.7] |
0.03 | – | - | - |
| Measurable LH**, age (y) | 9.01 ± 1.53 (13 pt) [6.0-11.3] |
9.58 ± 2.07 (4 pt) [6.6-11.3] |
8.75 ± 1.29 (9 pt) [6.0-10.1] |
10.67 ± 1.75 (16 pt) [7.4-14.0] |
0.01 | 0.20 | 0.49 | 0.005 |
| Measurable LH**, age (y) in males | 9.47 ± 1.50 (7 pt) [6.6-11.3] |
10.04 (4 pt) [6.6-11.3] |
9.08 (3 pt) [8.8-9.8] |
10.9 ± 1.72 (12 pt) [8.0-14] |
0.1 | – | – | - |
| Measurable LH**, age (y) in females | 8.47 ± 1.51 (6 pt) [6.0-10.1] |
0 pt | 8.01 (6 pt) [6.0-10.1] |
9.99 ± 1.90 (4 pt) [7.4-11.9] |
0.3 | – | – | - |
| Menarche age (y) | 11.11 ± 0.69 (5 pt) [10.0-11.8] |
10.91 ± 1.29 (2 pt) [10.0-11.8] |
11.23 ± 0.25 (3 pt) [11.0-11.5] |
11.86 ± 0.75 (4 pt) [10.9-12.7] |
0.29 | 1 | 0.53 | 0.40 |
y, years; SRS, Silver-Russell syndrome; 11p15, 11p15 loss of methylation; UPD7, maternal uniparental disomy of chromosome 7; pt, patients; LH, luteinizing hormone * 17- β -estradiol ≥ 5 pg/ml; testosterone ≥ 5 ng/dl. ** LH ≥ 0.1 U/L.
- not applicable because of the little number of patients.The bold numbers indicate a statically significant p-value ( p value ≤ 0.05).